tetano
Editor, Senior Moderator
CEN Case Rep
. 2021 Mar 26.
doi: 10.1007/s13730-021-00584-z. Online ahead of print.
COVID-19 progression in kidney transplant recipients: a single-center case series
Hormat Rahimzadeh[SUP] 1 2 3 [/SUP], Mohammad Keykhaei[SUP] 4 [/SUP], Effat Razeghi[SUP] 5 6 [/SUP], Ensieh Zivari[SUP] 5 [/SUP], Ensieh Sadat Mansouri[SUP] 7 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) is a respiratory infection that has received much attention due to its rapid expansion. Currently, it has been revealed that patients with underlying disease, especially those with kidney disease are more prone to develop complications. Some studies associate kidney transplantation as a risk factor for COVID-19 progression; however, epidemiologic data that demonstrate this are amazingly rare. Considering the importance of the topic, we report on six kidney transplant recipients (median age 47 [41-55]) with confirmed or clinically suspected COVID-19. The most common admission presentations were fever (83.3%), dyspnea, and myalgia. At baseline, immunosuppressive therapy was ceased, prednisolone dose was increased, and all patients received antiviral treatment including hydroxychloroquine and umifenovir. After a median follow-up of 11.5 days from admission, six patients (100%) developed acute kidney injury (AKI), 50% required intensive care unit (ICU) admission, and two patients (33.3%) deceased as a result of deterioration in respiratory status. Overall, these findings demonstrate that respiratory involvement may be a risk indicator of in-hospital mortality in kidney recipients with COVID-19. In addition, AKI development in kidney recipients with COVID-19 is of utmost importance given the higher AKI occurrence in these patients compared with others. Therefore, more intensive attention should be paid to kidney transplant recipients with COVID-19.
Keywords: AKI; COVID-19; Immunosuppression; Kidney transplant.
. 2021 Mar 26.
doi: 10.1007/s13730-021-00584-z. Online ahead of print.
COVID-19 progression in kidney transplant recipients: a single-center case series
Hormat Rahimzadeh[SUP] 1 2 3 [/SUP], Mohammad Keykhaei[SUP] 4 [/SUP], Effat Razeghi[SUP] 5 6 [/SUP], Ensieh Zivari[SUP] 5 [/SUP], Ensieh Sadat Mansouri[SUP] 7 [/SUP]
Affiliations
- PMID: 33770414
- DOI: 10.1007/s13730-021-00584-z
Abstract
The novel coronavirus disease 2019 (COVID-19) is a respiratory infection that has received much attention due to its rapid expansion. Currently, it has been revealed that patients with underlying disease, especially those with kidney disease are more prone to develop complications. Some studies associate kidney transplantation as a risk factor for COVID-19 progression; however, epidemiologic data that demonstrate this are amazingly rare. Considering the importance of the topic, we report on six kidney transplant recipients (median age 47 [41-55]) with confirmed or clinically suspected COVID-19. The most common admission presentations were fever (83.3%), dyspnea, and myalgia. At baseline, immunosuppressive therapy was ceased, prednisolone dose was increased, and all patients received antiviral treatment including hydroxychloroquine and umifenovir. After a median follow-up of 11.5 days from admission, six patients (100%) developed acute kidney injury (AKI), 50% required intensive care unit (ICU) admission, and two patients (33.3%) deceased as a result of deterioration in respiratory status. Overall, these findings demonstrate that respiratory involvement may be a risk indicator of in-hospital mortality in kidney recipients with COVID-19. In addition, AKI development in kidney recipients with COVID-19 is of utmost importance given the higher AKI occurrence in these patients compared with others. Therefore, more intensive attention should be paid to kidney transplant recipients with COVID-19.
Keywords: AKI; COVID-19; Immunosuppression; Kidney transplant.